본문 바로가기

Brentuximab Vedotin로 치료한 CD30 양성 대세포 이행을 보인 균상식육종 1예

CD30+ Large-Cell Transformation of Mycosis Fungoides Treated with Brentuximab Vedotin

문서 유형
연구출판물 · 학술지 논문
등재
KCIScopus
저널 순위
Scopus Q4KCI Q3
저널
대한피부과학회지60(2) · pp.106 · 2022
피인용
Scopus 0KCI 0
FWCI (Scopus)
0
ISSN
0494-4739

저자

  1. 신준오제1저자Department of Dermatology, School of Medicine, Pusan National University, Busan, Korea
  2. 배경남Department of Dermatology, School of Medicine, Pusan National University, Busan, Korea
  3. 손진화Department of Dermatology, School of Medicine, Pusan National University, Busan, Korea
  4. 신기혁Department of Dermatology, School of Medicine, Pusan National University, Busan, Korea
  5. 김훈수Department of Dermatology, School of Medicine, Pusan National University, Busan, Korea
  6. 고현창Department of Dermatology, School of Medicine, Pusan National University, Busan, Korea
  7. 김문범Department of Dermatology, School of Medicine, Pusan National University, Busan, Korea
  8. 김병수교신저자Department of Dermatology, School of Medicine, Pusan National University, Busan, Korea

초록

Large-cell transformation of mycosis fungoides (LCT-MF) is an advanced stage of primary cutaneous T-cell lymphoma with a poor prognosis. Therapeutic options for these patients are often limited, and so far, they are not promising. An 81-year-old woman with a previous history of mycosis fungoides presented with aggravation of generalized erythematous scaly patches and new onset of ulcerated tumor on the abdomen for 3 months. Histopathological examination revealed a dense dermal infiltrate composed of atypical large lymphocytes. Immunohistochemically, the tumor cells were positive for CD30 expression. A diagnosis of CD30+ LCT-MF was established. She was intensively treated with methotrexate (1 month), acitretin (1 month), and rituximab with dose-modified cyclophosphamide, doxorubicin, and prednisone (1 cycle). Despite such treatments, the improvement was minimal. Subsequently, the patient was started on brentuximab vedotin, 1.8 mg/kg intravenously once every 3 weeks. She responded well to brentuximab therapy, and the skin lesions completely subsided within 12 weeks of treatment

키워드

Cutaneous T-cell lymphomaMycosis fungoides

식별자

Scopus EID
2-s2.0-85137278967
KCI
ART002814589